SURF
Closed
Surface Oncology Inc
1.07
0.00 (0.00%)
Last Update: 12 Sep 2023 16:30:00
Yesterday: 1.07
Day's Range: 1.07 - 1.07
Send
sign up or login to leave a comment!
When Written:
0.6765
Surface Oncology Inc. is a clinical-stage immuno-oncology company that focuses on developing novel cancer therapies that target the immune system. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Surface Oncology's pipeline includes several product candidates, including SRF617, SRF388, SRF114, and SRF813, which are all in various stages of clinical development. The company's lead product candidate, SRF617, is a fully human monoclonal antibody that targets CD39, an enzyme that plays a key role in regulating the immune response in tumors.
Surface Oncology has collaborations with several pharmaceutical companies, including Novartis, Merck, and GlaxoSmithKline. The company has also raised significant funding through public offerings and private placements, with a total of over $200 million raised to date.
Surface Oncology's mission is to develop innovative cancer therapies that can improve the lives of patients with cancer. The company is committed to advancing its pipeline of product candidates and collaborating with other companies and organizations to accelerate the development of new cancer treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Surface Oncology's pipeline includes several product candidates, including SRF617, SRF388, SRF114, and SRF813, which are all in various stages of clinical development. The company's lead product candidate, SRF617, is a fully human monoclonal antibody that targets CD39, an enzyme that plays a key role in regulating the immune response in tumors.
Surface Oncology has collaborations with several pharmaceutical companies, including Novartis, Merck, and GlaxoSmithKline. The company has also raised significant funding through public offerings and private placements, with a total of over $200 million raised to date.
Surface Oncology's mission is to develop innovative cancer therapies that can improve the lives of patients with cancer. The company is committed to advancing its pipeline of product candidates and collaborating with other companies and organizations to accelerate the development of new cancer treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!